Fang Min, Cheng Hong, Dai Zhongping, Bu Zimei, Sigal Luis J
Program of Viral Pathogenesis, Division of Basic Science, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA.
Virology. 2006 Feb 5;345(1):231-43. doi: 10.1016/j.virol.2005.09.056. Epub 2005 Oct 25.
Subunit vaccines that use the vaccinia virus extracellular envelope protein A33R alone or combined with other structural proteins are excellent candidates for a new smallpox vaccine. Since a new smallpox vaccine would be used in humans, who are the natural hosts for the Orthopoxvirus variola, the agent of smallpox, it would be important to determine whether a prospective smallpox vaccine can protect from a lethal Orthopoxvirus infection in a natural host. We addressed this question using the mouse-specific Orthopoxvirus ectromelia virus. We demonstrate that immunization with recombinant ectromelia virus envelope protein EVM135 or its ortholog vaccinia virus A33R produced in E. coli protects susceptible mice from a lethal ectromelia virus infection. This is the first report that a subunit vaccine can provide protection to a lethal Orthopoxvirus infection in its natural host.
单独使用痘苗病毒细胞外包膜蛋白A33R或与其他结构蛋白联合使用的亚单位疫苗是新型天花疫苗的优秀候选者。由于新型天花疫苗将用于人类,而人类是天花病原体正痘病毒天花病毒的天然宿主,因此确定一种前瞻性天花疫苗能否在天然宿主中预防致死性正痘病毒感染非常重要。我们使用小鼠特异性正痘病毒埃可病毒来解决这个问题。我们证明,用重组埃可病毒包膜蛋白EVM135或其在大肠杆菌中产生的直系同源物痘苗病毒A33R进行免疫可保护易感小鼠免受致死性埃可病毒感染。这是第一份关于亚单位疫苗能在天然宿主中为致死性正痘病毒感染提供保护的报告。